Mbrace Therapeutics Raises $85 Million Series B Financing To Advance Oncology Pipeline Of Innovative Antibody Drug Conjugate Candidates
Mbrace Therapeutics Raises $85 Million Series B Financing To Advance Oncology Pipeline Of Innovative Antibody Drug Conjugate Candidates
11/14/23, 1:33 PM
Location
san diegoMoney raised
$85 million
Industry
medical
therapeutics
pharmaceutical
biotechnology
health care
Round Type
series b
Investors
Alta Partners, Venrock, Cowen Healthcare Investments, Avidity Partners, The Rise Fund, Tpg Life Sciences Innovations, Tpg
MBraceTM Therapeutics, Inc. (“MBrace”), a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, announced the completion of an $85 million Series B financing, bringing the company’s total raised to $110 million. Funds will be used to support clinical development programs, including a first-in-human clinical trial of lead investigational ADC, MBRC-101.
Company Info
Location
san diego, california, united states
Additional Info
MBrace is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutic agents for patients with cancer. MBrace develops innovative treatments for cancer patients by developing novel antibody-drug conjugates against targets identified using technology pioneered by its founders. MBrace is headquartered in San Diego, CA, with research facilities at The Thomas O. Daniel Research Incubator and Collaboration Center at Bristol Myers Squibb in Summit, NJ. For additional information, please visit MBrace’s website at http://www.mbracetrx.com.